5-Amino-1MQ 50mg Tablets (60 Count) Research Compound
5-Amino-1MQ (5-amino-1-methylquinolinium) in oral tablet form provides a convenient format for extended in vivo research protocols examining NNMT (nicotinamide N-methyltransferase) inhibition via oral administration. Each tablet contains 50mg of 5-Amino-1MQ — the selective, cell-permeable NNMT inhibitor studied for its effects on adipogenesis suppression, NAD+ pathway modulation, and cancer metabolism. This 60-tablet format is suited for longer-duration rodent metabolic studies or multi-dose in vitro protocols requiring larger quantities. Research-grade material at ≥99% purity per tablet.
Research Background
NNMT overexpression in adipose tissue consumes SAM (S-adenosyl methionine) and reduces NAD+ precursor availability through the NAMPT salvage pathway. 5-Amino-1MQ inhibits NNMT, redirecting nicotinamide toward NAD+ biosynthesis and increasing the SAM:SAH ratio — driving epigenetic and metabolic reprogramming in adipocyte and cancer cell models. Published mouse studies using oral and IP administration of NNMT inhibitors demonstrate significant reductions in body weight, fat mass, and plasma lipids in diet-induced obesity models, establishing oral bioavailability as a feature of this compound class.
Compound Specifications
- Format: Oral tablets
- Purity: ≥99% per tablet (HPLC verified)
- Quantity: 60 tablets × 50mg 5-Amino-1MQ
- Storage: Cool, dry place, protected from light
- Target: NNMT inhibitor
- Molecular Weight: 174.2 Da
Certificate of Analysis
Third-party tested by independent ISO-certified laboratories. HPLC validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
